FDA Designates Cannabis Pain Drug VER-01 as Breakthrough Therapy

The US Food and Drug Administration granted Breakthrough Therapy Designation to VER-01, a full-spectrum cannabis extract developed by Munich-based Vertanical, on May 18, 2026 — positioning it as a potential first FDA-approved cannabis-derived medicine for chronic pain, a category where no plant-derived cannabis drug has ever cleared the agency’s review.

The designation was confirmed by Vertanical in a press release on May 18, 2026 and was built on results from two European Phase 3 randomized controlled trials. The FDA’s breakthrough pathway is reserved for investigational drugs showing preliminary evidence of substantial improvement over existing therapies for serious conditions. It does not confer approval — but it signals that the agency sees enough in VER-01’s clinical evidence package to expedite its development and review through intensive FDA guidance.

The only FDA-approved cannabis-derived drug to date is Epidiolex, Jazz Pharmaceuticals’ (JAZZ ) CBD-based treatment for rare pediatric epilepsies, approved in 2018. Synthetic cannabinoid drugs Marinol and Syndros are already federally classified as Schedule III but are not derived from the plant. VER-01’s pathway to market runs through a New Drug Application submission, currently targeting 2028 at the earliest.

What the trials showed

The breakthrough designation rests on two Phase 3 RCTs. The first — a placebo-controlled trial of 820 patients published in Nature Medicine in September 2025 (registered as NCT04940741) — found VER-01 met its primary pain endpoint: significant reduction compared with placebo, with effects maintained over 12 months and improvements in sleep interference and physical function. Participants had chronic low back pain and prior failures with standard non-opioid treatments.

The second, a head-to-head comparator trial of 384 patients, was published in Pain and Therapy in September 2025 (PMID 41028525). Conducted across 41 sites in Germany, the Czech Republic, Poland, and Spain, it randomized participants to VER-01 or a range of commercially available opioids. The primary endpoint was gastrointestinal tolerability: VER-01 patients were fourfold less likely to develop constipation than those on opioids (relative risk 0.25; 95% CI 0.09–0.69; p=0.007) and threefold less likely to need laxatives. Over six months, mean pain reduction was 2.50 numeric rating scale points with VER-01 versus 2.16 with opioids — a mean difference of 0.34 points (p=0.048), with a parallel advantage in sleep interference scores (mean difference 0.45; p=0.009).

There are methodological caveats that matter. The head-to-head trial was open-label — no blinding, by necessity — which introduces bias risk. The pain endpoint at week 27 alone did not reach statistical significance; the published efficacy finding came from the longitudinal analysis across the full six months. The effect sizes, while statistically significant, are modest on absolute terms: a 0.34-point pain difference on an 11-point scale. What mitigates that somewhat is the patient population — people who had already failed optimized non-opioid analgesics, where the threshold for clinical relevance on a chronic basis differs from that in naïve populations. The trial was sponsored by Vertanical GmbH.

Where the data hold up more cleanly is on tolerability. Constipation affects an estimated 40 to 60 percent of patients on long-term opioid therapy; fewer than 6 percent of VER-01 patients in the comparator trial developed it, versus over 23 percent in the opioid arm. Across 12 months of the placebo-controlled trial, no adverse events indicating drug abuse, dependence, or withdrawal were reported. When VER-01 was stopped abruptly at the end of the comparator trial, no withdrawal signals emerged — a meaningful contrast with the two-week opioid taper the comparator arm required.

VER-01 is a standardized full-spectrum extract from the proprietary Cannabis sativa strain DKJ127 L., standardized to 21 mg THC per gram and containing cannabigerol, β-caryophyllene, and α-bisabolol among its bioactive constituents. It is taken orally as liquid drops. Vertanical is explicit that findings from these trials cannot be extrapolated to other cannabis extracts, isolated cannabinoids, or cannabis flower — the extract’s specific phytochemical composition is load-bearing to the results.

What comes next

The breakthrough designation accelerates FDA engagement — intensive agency guidance beginning early in the development process — but it does not compress the evidence requirements. Vertanical has initiated an additional pivotal Phase 3 trial in the United States, designed specifically to confirm VER-01’s efficacy and safety in US patients. A first data read-out is expected in 2027, with a New Drug Application submission planned for 2028 if results are positive.

European authorization is the closer milestone. Vertanical expects approval from the first European markets within weeks. Germany is the expected lead jurisdiction; once it grants marketing authorization, the EU’s mutual recognition procedure would be the route to broader continental access. The drug will be sold under the brand name Exilby. The development program has taken seven years and cost the company over $250 million.

The US regulatory backdrop adds context. Cannabis was formally reclassified to Schedule III in 2026, but there are two legally distinct tracks under that change: FDA-approved cannabis-derived drugs, and state-licensed cannabis products. Epidiolex sits in the first category; VER-01, if the NDA clears, would join it. Drugs in that first category qualify for standard hospital formularies and insurance reimbursement negotiation, and can be prescribed by any licensed physician without the compliance architecture that state-licensed operators must navigate.

Chronic low back pain affects an estimated 500 million people globally. The European trial program has produced two peer-reviewed Phase 3 datasets, and the Nature Medicine publication represents a meaningful quality bar for a cannabis-derived therapeutic. Whether the US trial — designed to meet FDA-specific requirements — replicates those results is where the clinical story remains open.